Abstract
A study of 4-acylaminobenzenesulfonamides in a cloned human beta 3 adrenergic receptor assay resulted in the discovery of n-hexylurea, L-755,507 (22). This 0.43 nM beta 3 agonist, which is > 440-fold selective over both beta 1 and beta 2 binding, is among the most potent human beta 3 agonists reported to date.
4-Acylaminobenzenesulfonamides were studied in a cloned human β3 adrenergic receptor assay. This led to the discovery of n-hexylurea, L-755,507 (22), a 0.43 nM β3 agonist which is > 440-fold selective over both β1 and β2 binding.